![]() |
Name |
cis-2-Tridecene
|
Molecular Formula | C13H26 | |
IUPAC Name* |
(Z)-tridec-2-ene
|
|
SMILES |
CCCCCCCCCC/C=C\C
|
|
InChI |
InChI=1S/C13H26/c1-3-5-7-9-11-13-12-10-8-6-4-2/h3,5H,4,6-13H2,1-2H3/b5-3-
|
|
InChIKey |
XWVHBWQEYOROBE-HYXAFXHYSA-N
|
|
Synonyms |
cis-2-Tridecene; 2-Tridecene, (Z)-; (2Z)-2-Tridecene; 2-Tridecene, (Z); 2-Tridecene, (2Z)-; 41446-59-7; DA9736F843; (z)-2-tridecene; Z-2-TRIDECENE; .BETA.-CIS-TRIDECENE; UNII-DA9736F843; DTXSID00880864; Q27276306
|
|
CAS | 41446-59-7 | |
PubChem CID | 5362714 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 182.35 | ALogp: | 7.0 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 13 | QED Weighted: | 0.33 |
Caco-2 Permeability: | -4.66 | MDCK Permeability: | 0.00001770 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.818 |
30% Bioavailability (F30%): | 0.996 |
Blood-Brain-Barrier Penetration (BBB): | 0.696 | Plasma Protein Binding (PPB): | 97.79% |
Volume Distribution (VD): | 3.722 | Fu: | 2.69% |
CYP1A2-inhibitor: | 0.826 | CYP1A2-substrate: | 0.453 |
CYP2C19-inhibitor: | 0.543 | CYP2C19-substrate: | 0.235 |
CYP2C9-inhibitor: | 0.297 | CYP2C9-substrate: | 0.942 |
CYP2D6-inhibitor: | 0.296 | CYP2D6-substrate: | 0.492 |
CYP3A4-inhibitor: | 0.278 | CYP3A4-substrate: | 0.108 |
Clearance (CL): | 4.708 | Half-life (T1/2): | 0.57 |
hERG Blockers: | 0.119 | Human Hepatotoxicity (H-HT): | 0.033 |
Drug-inuced Liver Injury (DILI): | 0.083 | AMES Toxicity: | 0.018 |
Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.042 |
Skin Sensitization: | 0.946 | Carcinogencity: | 0.053 |
Eye Corrosion: | 0.989 | Eye Irritation: | 0.987 |
Respiratory Toxicity: | 0.551 |